A Clinical Study to Evaluate the KeraKlear Keratoprosthesis in Patients With Corneal Opacity

Corneal Blindness Clinical Trial

Official title:
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Probable Benefit of the KeraKlear Non-Penetrating Keratoprosthesis in Subjects With Corneal Opacity With Poor Prognosis for Corneal Transplant

Status Terminated

Clinical Trial Summary

To evaluate the safety and probable benefit of the KeraKlear Non-Penetrating Keratoprosthesis when implanted in an eye with corneal opacity that is at high risk of complications with PK.

Clinical Trial Description

To evaluate the safety and probable benefit of the KeraKlear Non-Penetrating Keratoprosthesis when implanted in an eye with corneal opacity that is at high risk of complications with PK. A prospective, multicenter, clinical trial, designed to demonstrate the safety and performance of the KeraKlear Non-Penetrating Keratoprosthesis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03126903
Study type	Interventional
Source	KeraMed, Inc.
Contact
Status	Terminated
Phase	N/A
Start date	March 22, 2018
Completion date	November 30, 2019

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01950598` - Frozen Versus Fresh Corneal Carriers for the Boston KPro Type I Donor Carriers	N/A
	Withdrawn	`NCT01256489` - Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)	Phase 1/Phase 2